Nesfatin‐1 Reduces Cholic Acid‐Induced Intrahepatic Cholestasis of Pregnancy by Regulating the General Control Nonderepressible 2/Eukaryotic Initiation Factor 2α Pathway
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70147 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2025. Written by Yong Liang and 4 co-authors. Institution: Department of Obstetrics, The First Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang, China. Major MEDLINE topics: Cholestasis, Intrahepatic, Cholic Acid, Pregnancy Complications, Eukaryotic Initiation Factor-2. 38 references. Funded by: the Project for the Construction of Inheritance Workshops of Famous Traditional Chinese Medicine Practitioners in Guizhou, Guizhou University of Traditional Chinese Medicine 2024 Youth Sail Plan Project.
Abstract (original language)
Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that significantly impacts pregnancy outcomes, with oxidative stress (OS) playing a crucial role in its pathogenesis. The animal model was constructed using 8–10‐week‐old CD‐1 mice, which were administered cholic acid (CA) orally from gestational day (GD) 12–GD17 to induce placental injury. Nesfatin‐1 (NF‐1) was administered intraperitoneally to assess its protective effects. Our study found that NF‐1 effectively attenuated placental dysfunction by reducing glucocorticoid (GC) production and boosting 11β‐hydroxysteroid dehydrogenase type 2 (11β‐HSD2) expression, a key enzyme for GC inactivation. Furthermore, NF‐1 reduced OS markers such as malondialdehyde (MDA) and reactive oxygen species (ROS) in both placental tissue and HTR8/SVneo cells. The protective effects of NF‐1 were correlated with the suppression of the general control nonderepressible 2 (GCN2)/eukaryotic initiation factor 2α (eIF2α) signaling pathway, which became activated under OS conditions. Notably, halofuginone, a GCN2 agonist, abolished the beneficial effects of NF‐1, further confirming the involvement of the GCN2/eIF2α pathway. These results suggest that NF‐1 may serve as a potential therapeutic agent for managing ICP and related stress‐induced pregnancy complications by modulating GC metabolism and mitigating OS.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Obstetrics, The First Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang, China.
ORCID profiles: Shuhan Lv
Funding
- the Project for the Construction of Inheritance Workshops of Famous Traditional Chinese Medicine Practitioners in Guizhou
- Guizhou University of Traditional Chinese Medicine 2024 Youth Sail Plan Project
Cite
APA
Liang, Y., Wen, X., Sun, Z., Meng, Y., & Lv, S. (2025). Nesfatin‐1 Reduces Cholic Acid‐Induced Intrahepatic Cholestasis of Pregnancy by Regulating the General Control Nonderepressible 2/Eukaryotic Initiation Factor 2α Pathway. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70147
Vancouver
Liang Y, Wen X, Sun Z, Meng Y, Lv S. Nesfatin‐1 Reduces Cholic Acid‐Induced Intrahepatic Cholestasis of Pregnancy by Regulating the General Control Nonderepressible 2/Eukaryotic Initiation Factor 2α Pathway. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70147
BibTeX
@article{Liang2025,
author = {Liang, Yong and Wen, Xiaomin and Sun, Zhe and Meng, Yuqiong and Lv, Shuhan},
title = {Nesfatin‐1 Reduces Cholic Acid‐Induced Intrahepatic Cholestasis of Pregnancy by Regulating the General Control Nonderepressible 2/Eukaryotic Initiation Factor 2α Pathway},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70147}
}
EUVIMED